Immunocore Holdings plc has released a corporate presentation detailing their advancements in developing transformative immunomodulating medicines. The presentation highlights the company's focus on harnessing the immune system to combat diseases using targeted, off-the-shelf, bispecific, soluble T cell receptors (TCRs). These TCR therapeutics are capable of targeting over 90% of the human proteome, with applications across oncology, infectious diseases, and autoimmune diseases. Key projects include ongoing Phase 1 and Phase 2 trials for multiple solid tumors, colorectal and GI cancers, HIV, Hepatitis B, Type 1 Diabetes, and Atopic Dermatitis. The company continues to develop its bispecific TCR pipeline, with ongoing and upcoming trials in different stages. You can access the full presentation through the link below.